Health Care [ 10/12 ] | Biotechnology [ 39/73 ]
NASDAQ | Common Stock
Immunome, Inc., a clinical-stage biotechnology company, develops targeted cancer therapies.
The company's clinical asset comprises Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial.
Its preclinical assets include IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, including IM-1617, IM-1340, and IM-1335.
Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 6, 25 | -0.50 Decreased by -2.04% | -0.62 Increased by +19.59% |
| May 12, 25 | -0.52 Increased by +79.28% | -0.81 Increased by +35.80% |
| Mar 26, 25 | -1.11 Increased by +73.70% | -0.61 Decreased by -82.72% |
| Nov 7, 24 | -0.78 Decreased by -116.67% | -0.56 Decreased by -39.29% |
| Aug 9, 24 | -0.49 Decreased by -6.52% | -0.39 Decreased by -25.64% |
| May 14, 24 | -2.51 Decreased by -617.14% | -0.69 Decreased by -263.77% |
| Mar 28, 24 | -4.22 Decreased by -559.37% | -0.28 Decreased by -1.41 K% |
| Nov 9, 23 | -0.36 Increased by +52.00% | -0.17 Decreased by -111.76% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 25 | 4.01 M Increased by +69.84% | -43.40 M Decreased by -20.14% | Decreased by -1.08 K% Increased by +29.26% |
| Mar 31, 25 | 2.93 M Increased by +184.35% | -41.64 M Increased by +67.84% | Decreased by -1.42 K% Increased by +88.69% |
| Dec 31, 24 | 2.74 M Decreased by -28.44% | -80.25 M Increased by +13.37% | Decreased by -2.93 K% Decreased by -21.05% |
| Sep 30, 24 | 2.91 M Decreased by -18.37% | -47.10 M Decreased by -984.00% | Decreased by -1.62 K% Decreased by -1.23 K% |
| Jun 30, 24 | 2.36 M Decreased by -44.55% | -36.12 M Decreased by -550.03% | Decreased by -1.53 K% Decreased by -1.07 K% |
| Mar 31, 24 | 1.03 M Decreased by -56.47% | -129.49 M Decreased by -3.08 K% | Decreased by -12.58 K% Decreased by -7.21 K% |
| Dec 31, 23 | 3.83 M Increased by +N/A% | -92.63 M Decreased by -1.00 K% | Decreased by -2.42 K% Decreased by N/A% |
| Sep 30, 23 | 3.56 M Increased by +N/A% | -4.34 M Increased by +49.07% | Decreased by -121.88% Decreased by N/A% |